Tagraxofusp: Phase 1 Study (+/- chemotherapy) in Pediatric Patients with R/R CD123 expressing Heme Malignancies

Phase I Study of Tagraxofusp +/- Chemotherapy in Pediatric Patients with R/R CD123-Expressing Hematologic Malignancies: A TACL Consortium Trial. ASH 2022. Poster


Tagraxofusp: Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial

Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial. ASH 2022. Poster


Tagraxofusp: Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP

Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP. ASH 2022. Poster


Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF

Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF. ASH 2021. Oral Presentation


Tagraxofusp in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

TAG in Patients with CMML: Updated Results from Phase 1/2 Trial. ASH 2021. Oral Presentation


Tagraxofusp: Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease

Tagraxofusp Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease. ASH 2021. Oral Presentation


Tagraxofusp: Safety and Efficacy of Combing TAG with AZA and AZA+VEN

Safety and Efficacy of Combining Tagraxofusp with AZA or AZA+VEN in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. ASH 2021. Poster


Tagraxofusp: A Multicenter Phase 1/2 Trial in Patients with Poor-Risk MF

A Multicenter Phase 1/2 Trial of Tagraxofusp in Patients with Poor-Risk MF. ASH 2020. Poster


Tagraxofusp Alone and in Combination with Ruxolitinib for Treatment of Myeloproliferative Neoplasms

Evaluation of Tagraxofusp(SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms. ASH 2019. Poster


Results from Clinical Trial of Tagraxofusp in Patients with Intermediate or High Risk R/R MF

Results from Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASH 2019. Oral Presentation